Imperative Care, Inc. today announced three appointments to the company’s Board of Directors with the addition of Holly Sheffield, Hank Plain, and James Rogers.

“We are grateful to have the guidance of Holly, Hank, and James as they bring distinctive and complementary industry leadership to Imperative Care as we continue to accelerate our development and commercialization efforts,” said Fred Khosravi, Chairman and CEO of Imperative Care. “Having these high-caliber professionals join our Board speaks to the potential of our programs in bringing more innovative technologies to market faster and meeting patients’ needs in the fields of stroke and peripheral vascular disease.”

After a distinguished career of more than 20 years in investment banking, Holly Sheffield joined CooperCompanies (NYSE: COO) as Executive Vice President, Chief Strategy Officer in June of 2018. Last year, Holly was named President of CooperSurgical, one of Cooper Companies’ two business units. CooperSurgical is focused on advancing the standard of healthcare for women and families worldwide. Prior to this, she was Managing Director and Global Head of Medical Technology Investment Banking at UBS Securities. She also worked at Donaldson, Lufkin & Jenrette, where she started in 1997, until its acquisition by Credit Suisse, where she stayed as a Managing Director until 2009. Holly is a graduate of Cornell University and obtained her MBA from Columbia University.

Before transitioning to the world of venture capital, Hank Plain began his highly successful career in the pharmaceutical and medical device industries more than 40 years ago. As the CEO of Perclose, he led the company through a successful IPO and acquisition by Abbott Laboratories. Following this, he co-founded eight medical device companies as part of his work at The Foundry medical device incubator. In addition to currently serving as Partner of Morgenthaler Ventures and Lightstone Ventures, he is on numerous Boards including Nuvaira, Moximed, Earlens and Setpoint. He also serves as Chairman of the Board of Trustees for the Naval Postgraduate School Foundation and on the Future Citizens Foundation/First Tee Board. He is a graduate of the University of Missouri with a B.S. in Finance.

James Rogers is an Analyst at D1 Capital Partners, the lead investor in Imperative Care’s $260 million Series D financing announced last month. Since D1 launched in July 2018, James has led over a dozen private financings, including investments in innovative medical technology companies such as Auris Health, Outset Medical (NASDAQ: OM), and Sight Sciences (NASDAQ: SGHT). Previously, he was a Principal at Valinor Management and an Analyst at The Blackstone Group. James graduated from the University of Virginia with a B.S. in Commerce and a B.A. in History as a Jefferson Scholar and an Echols Scholar.

“Imperative Care’s intentional mission to impact the continuum of stroke care and vascular thrombectomy, elevating innovations in order to make more care available to more patients globally, requires a Board with a long-term horizon and broad expertise. Holly, Hank and James will further strengthen the tremendous prowess of the existing Imperative Care Board, to help achieve this important mission. We are delighted to have them on the team,” said John Hamre, Ph.D., Chairman of the Nominating and Governance Committee of the Imperative Care’s Board of Directors.

About Imperative Care, Inc.

Imperative Care is a vascular technology company focused on developing the next generation of innovative solutions to address the vast and urgent needs in stroke. The company has two 510(k) cleared product platforms, as well as an expansive stroke technology development pipeline. In addition, Imperative Care’s wholly owned subsidiary, Truvic Medical, Inc., is developing solutions for the treatment of peripheral vascular disease. Imperative Care and Truvic Medical are based in Campbell, Calif.

For more information, visit www.imperativecare.com and www.truvic.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210820005043/en/